Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of Oral GC4702 in Healthy Volunteers
NCT03096756Phase 1Completed
- Sponsor
- Galera Therapeutics, Inc.
- Start
- Jul 2016
- Primary completion
- Dec 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of GC4702 in oral mucositis (OM) (2 arms), sponsored by Galera Therapeutics, Inc. Primary endpoint: Incidence of Treatment-Emergent Adverse Events and Laboratory Abnormalities. Started Jul 2016; status: completed.
02
Drugs
GC4702
03
Conditions
oral mucositis (OM)
Beyond the preview
Go deeper on NCT03096756.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03096756.